相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs
Ying Hong Li et al.
BRIEFINGS IN BIOINFORMATICS (2020)
Antimicrobial peptides as novel therapeutics for non-small cell lung cancer
Nitesh K. Kunda
DRUG DISCOVERY TODAY (2020)
Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy
Brizaida Oliva Arguelles et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer
Ning An et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis
Lijun Gu et al.
PLOS ONE (2018)
Role of the NFκB-signaling pathway in cancer
Longzheng Xia et al.
ONCOTARGETS AND THERAPY (2018)
The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552
Maribel G. Vallespi et al.
RESEARCH IN VETERINARY SCIENCE (2017)
Glycine decarboxylase and HIF-1α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer
Sabina Berezowska et al.
VIRCHOWS ARCHIV (2017)
Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications
Berthony Deslouches et al.
ONCOTARGET (2017)
A systematic analysis of FDA-approved anticancer drugs
Jingchun Sun et al.
BMC SYSTEMS BIOLOGY (2017)
Evaluation of the use of therapeutic peptides for cancer treatment
Susan Marqus et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic
Ayelet Ollech et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552
Soledad Astrada et al.
JOURNAL OF PEPTIDE SCIENCE (2016)
Prognostic value of plasma levels of HIF-1β and PGC-1β in breast cancer
Feng-Feng Cai et al.
ONCOTARGET (2016)
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
M. R. Sarduy et al.
BRITISH JOURNAL OF CANCER (2015)
Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells
Teresa Nunez de Villavicencio-Diaz et al.
JOURNAL OF PROTEOMICS (2015)
Proteomic Study to Survey the CIGB-552 Antitumor Effect
Arielis Rodriguez-Ulloa et al.
BIOMED RESEARCH INTERNATIONAL (2015)
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky et al.
CLINICAL CANCER RESEARCH (2014)
Copper Metabolism Domain-Containing 1 Represses Genes That Promote Inflammation and Protects Mice From Colitis and Colitis-Associated Cancer
Haiying Li et al.
GASTROENTEROLOGY (2014)
Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models
Maribel G. Vallespi et al.
JOURNAL OF PEPTIDE SCIENCE (2014)
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor
Hasan Mutlu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
M. A. Warso et al.
BRITISH JOURNAL OF CANCER (2013)
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer
Taofeek K. Owonikoko et al.
CANCER (2013)
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
C. Dudgeon et al.
ONCOGENE (2012)
Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma
Samaneh Boroumand-Noughabi et al.
BMC CANCER (2010)
Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection
I-Hsuan Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
COMMD1 disrupts HIF-1 alpha/beta dimerization and inhibits human tumor cell invasion
Bart van de Sluis et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region
Maribel G. Vallespi et al.
JOURNAL OF PEPTIDE SCIENCE (2010)
NF-kappa B and Bcl-3 Activation Are Prognostic in Metastatic Colorectal Cancer
Soham D. Puvvada et al.
ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Nuclear-Cytosolic Transport of COMMD1 Regulates NF-κB and HIF-1 Activity
Patricia A. J. Muller et al.
TRAFFIC (2009)
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
P. J. Lowe et al.
XENOBIOTICA (2007)
COMMD proteins and the control of the NFκB pathway
Gabriel N. Maine et al.
CELL CYCLE (2007)
NF-κB in solid tumors
Francesco Pacifico et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Nuclear factor (NF)-κB proteins:: therapeutic targets
IM Verma
ANNALS OF THE RHEUMATIC DISEASES (2004)
A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases
MG Vallespi et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2000)
分享论文
